Head-to-head evidence
Henagliflozin vs SYR-472
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Henagliflozin
Developed by Jiangsu Hengrui Pharmaceuticals
NCT03159052 · Phase 3 · status unknown
This was a randomized, quadruple-blind, placebo-controlled trial (n=450). The primary endpoint, HbA1c change at 24 weeks, was clearly met: both the 5 mg and 10 mg doses reduced HbA1c significantly more than placebo (p<.001 for each).
Next expected readout: December 2026 · NCT06448130 (registry estimate)
SYR-472
Developed by Takeda Pharmaceutical Company
NCT02324569 · Phase 3 · completed
The 12-week comparison randomized 240 participants and used quadruple blinding with placebo control. The primary HbA1c endpoint was met, with a statistically significant treatment difference, but HbA1c is a surrogate laboratory measure rather than a hard clinical endpoint; the subsequent long-term period was open-label.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Henagliflozin's landscape · SYR-472's landscape